We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly PR Newswire LUND, Sweden, July 17, 2023 Favorable safety...
Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly PR Newswire LUND, Sweden, July 17, 2023 Favorable safety...
Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder PR Newswire LUND, Sweden, May 24, 2023 Brixadi is the first treatment for opioid use...
Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder PR Newswire LUND, Sweden, May 24, 2023 Brixadi is the first treatment for opioid use...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 101.2 | 101.2 | 101.2 | 67443 | 101.2 | DE |
4 | 0 | 0 | 101.2 | 101.2 | 101.2 | 24144 | 101.2 | DE |
12 | 0 | 0 | 101.2 | 101.2 | 101.2 | 23230 | 101.2 | DE |
26 | 0 | 0 | 101.2 | 101.2 | 101.2 | 27596 | 101.2 | DE |
52 | 0 | 0 | 101.2 | 101.2 | 101.2 | 20456 | 101.2 | DE |
156 | 0 | 0 | 101.2 | 101.2 | 101.2 | 10563 | 101.2 | DE |
260 | 0 | 0 | 101.2 | 101.2 | 101.2 | 7902 | 101.2 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions